Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inception 2 Inc.

Latest From Inception 2 Inc.

Here To Stay: Inception Sciences Shows Why Build-To-Buy Works

Born at a time when venture capital found few exit opportunities for early-stage companies, build-to-buy helped mitigate the risk in investing in uncharted science. But the model is flourishing even in this period of wider capital options.

BioPharmaceutical Strategy

Versant Ventures Looks To Canada, Europe For New Deals

Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”

BioPharmaceutical United States

Biopharma Dealmaking Quarterly Statistics, Q4 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

BioPharmaceutical Deals

NeXeption, Not The Rule: Another Twist On Asset-Based Financing

As VCs experiment with new models for single-asset companies, new entrant NeXeption is trying something similar without raising its own fund. Can it wring enough value from the best assets pharmas are neglecting, without giving too much back to their original owners?

BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Inception 2 Inc.
  • Senior Management
  • Peppi Prasit, PhD, CEO
  • Contact Info
  • Inception 2 Inc.
    Phone: (858) 224-7700
    5871 Oberlin Dr.
    Ste. 100
    San Diego, CA 92121
    USA
UsernamePublicRestriction

Register